BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 3118717)

  • 21. The morphologic response of the human endometrium to long-term treatment with progestational agents.
    Ludwig H
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):796-808. PubMed ID: 7065058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical use of oestrogens and progestogens.
    Lauritzen C
    Maturitas; 1990 Sep; 12(3):199-214. PubMed ID: 2215269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the combined steroidal contraceptives (Gynanovlar 21 and Lyndiol 2.5) on the human adrenocortical and ovarian activities.
    Zaki K; Kamal I; Talaat MM; Rashad S; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):41-65. PubMed ID: 12256027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial effects of levonorgestrel and estradiol: A Scanning electron microscopic study of the luminal epithelium.
    Nilsson O; Englund D; Weiner E; Victor A
    Contraception; 1980 Jul; 22(1):71-83. PubMed ID: 6774851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy.
    Whitehead MI; King RJ; McQueen J; Campbell S
    J R Soc Med; 1979 May; 72(5):322-7. PubMed ID: 552525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The triphasic pill].
    Belaisch J
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):368-72. PubMed ID: 12280209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potency of progestogens in oral contraceptives--further delay of menses data.
    Swyer GI
    Contraception; 1982 Jul; 26(1):23-7. PubMed ID: 7128131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
    Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR; Gaspard UJ
    Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial.
    Notelovitz M; Feldman EB; Gillespy M; Gudat J
    Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1269-80. PubMed ID: 2655452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE; Berger GM; Maritz JS
    S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.
    Wilde MI; Balfour JA
    Drugs; 1995 Aug; 50(2):364-95. PubMed ID: 8521763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
    Daly L; Bonnar J
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):430-7. PubMed ID: 2142580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E; Mälkönen M; Manninen V
    N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.